BG Hennig /Viatris /Puren GbR

Track this competitor Create a free account to be notified when it wins a contract.

Contracts won: 1
Shared contracts: 1 (multi-supplier framework agreements)
Period: 7 August 2026 – 7 August 2026

Its main clients

DAK-Gesundheit · 1 contract

Where and what

Supplies · 1

Its contracts coming to an end

So many opportunities to take over these contracts when they are re-tendered.

Planned end	Contract	Current holder	Amount
6 July 2029 re-tender around January 2029	Generika-Ersatzkassen 29 DAK-Gesundheit framework agreement	PUREN Pharma GmbH & Co. KG Viatris Healthcare GmbH, Zweigniederlassung Bad Homburg Recordati Rare Diseases Germany GmbH Glenmark Arzneimittel GmbH Aristo Pharma GmbH BG ALIUD / STADAPHARM GbR Accord Healthcare S.L.U. vertreten durch Accord Healthcare GmbH Phoenix Labs Unlimited Company Grünenthal GmbH HEC Pharm GmbH BG Hexal 1A Pharma GbR Micro Labs GmbH BG Heumann / Heunet GbR Zentiva Pharma GmbH BG TEVA ratiopharm GbR Besins Healthcare Germany GmbH Organon Healthcare GmbH betapharm Arzneimittel GmbH hameln pharma Amarox Pharma GmbH TAD Pharma GmbH Dr. Falk Pharma GmbH PRO.MED.CS Praha a.s. Dexcel Pharma GmbH Medical Valley Invest AB Abanta Pharma GmbH Accord Healthcare GmbH 089Pharm GmbH Ascend GmbH BG Heumann / G.L. Pharma GbR BG Hennig /Viatris /Puren GbR BG Zentiva/Aristo/1A Pharma GbR Basics GmbH neuraxpharm Arzneimittel GmbH Phoenix Labs Unlimetid Company BG Hexal 1A Phama GbR Sun Pharmaceutical 13 bids received	€218,240,377

Contracts won

Date	Contract	Buyer	Amount
07/08/2026	Generika-Ersatzkassen 29	DAK-Gesundheit	€218,240,377 shared by 38

Source: contract award notices published on TED (Publications Office of the European Union), above the EU thresholds. Contracts published only in Belgium are not included yet.